Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: Harris Poll; Chart: Will Chase/Axios

Publicity surrounding the Johnson & Johnson vaccine's possible link to blood clots has had a negative effect on overall public opinion on vaccines, according to new Harris polling.

By the numbers: 54% of respondents said they wouldn't be willing to take the J&J vaccine in the future, even if its use is given the go-ahead by federal regulators.

  • Among those who were already skeptical of the vaccines — or who said they will “wait awhile and see” before taking the vaccine — well over half said the pause makes them more hesitant about vaccine safety overall.
  • The news also negatively impacted the opinions of people who said they won't take the vaccine.
  • And despite the rarity of blood clots among those who got the J&J vaccine, 69% of respondents said they are very or somewhat concerned about the link. 80% of those who want to wait and see before getting the vaccine said the same.

All of that said, 77% of respondents said they strongly or somewhat support the decision to pause use of the vaccine.

What we're watching: An independent advisory committee will meet again today about whether to resume use of the vaccine.

  • But only slightly more than half of respondents think use of the vaccine should be resumed if it's linked to rare blood clots.

Go deeper

Apr 23, 2021 - Health

The next generation of coronavirus vaccines won't come as quickly

Illustration: Aïda Amer/Axios

A flood of cash from Operation Warp Speed helped coax a slew of biotech companies into the race for a coronavirus vaccine, but the incentives to keep working on new competitors won't be nearly as strong.

Why it matters: That initial flood of cash worked — it delivered multiple, highly effective vaccines in record time. In other disease areas, though, second- and third-generation vaccines usually become the dominant products. And the first COVID-19 vaccines aren't necessarily a great fit for the whole world.

Updated 13 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Brendan Lynch/Axios

  1. Vaccines: Benefits of J&J COVID-19 vaccine outweigh risks, per CDC data — Vaccine boosters are increasingly likely.
  2. Health: Some states trim COVID reporting as Delta cases surge — Fauci: New masking guidelines for vaccinated Americans under "active consideration".
  3. Politics: White House boosts funding for COVID testing in vulnerable communities — Prominent Republicans find new enthusiasm for COVID-19 vaccines.
  4. Sports: Golfer Bryson DeChambeau will miss Olympics after testing positive for COVID— NFL raises vaccine pressure
  5. World: Israel to require vaccine certificates to attend social events.
  6. Variant tracker: Where different strains are spreading.
Apr 23, 2021 - Health

Washington state enters 4th COVID-19 surge, says governor

Washington State Gov. Jay Inslee. Photo: John Moore/Getty Images

Washington state has entered its fourth wave of the COVID-19 pandemic, Gov. Jay Inslee (D) announced during a press conference on Thursday.

Why it matters: Washington — like other states such as Michigan — is experiencing a surge in COVID cases driven largely by variants of the virus, predominantly the one first discovered in the U.K.